Clinical Trial Update: 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating 4'-Iodo-4'-Deoxydoxorubicin in patients with AL amyloidosis and related plasma cell neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• 4'-Iodo-4'-Deoxydoxorubicin (4'-Iodo-4'-deoxydoxorubicin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED